TrialJournal for immunotherapy of cancer2021

Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.

David Gandara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.